CSL Gestione

Gestione criteri di controllo 1/4

CSL Il CEO è Paul McKenzie, nominato in Mar2023, e ha un mandato di 1.67 anni. la retribuzione annua totale è $ 8.18M, composta da 23.1% di stipendio e 76.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.005% delle azioni della società, per un valore di € 3.96M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.7 anni e 4.9 anni.

Informazioni chiave

Paul McKenzie

Amministratore delegato

US$8.2m

Compenso totale

Percentuale dello stipendio del CEO	23.1%
Mandato del CEO	1.7yrs
Proprietà del CEO	0.005%
Durata media del management	1.7yrs
Durata media del Consiglio di amministrazione	4.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Paul McKenzie rispetto agli utili di CSL?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	US$8m	US$2m	US$3b
Mar 31 2024	n/a	n/a	US$3b
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	n/a	n/a	US$2b
Jun 30 2023	US$4m	US$1m	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	US$5m	US$965k	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	US$6m	US$989k	US$2b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	n/a	n/a	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	US$7m	US$1m	US$2b

Compensazione vs Mercato: La retribuzione totale di Paul ($USD 8.18M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 4.86M ).

Compensazione vs guadagni: La retribuzione di Paul è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Paul McKenzie (58 yo)

1.7yrs

Mandato

US$8,183,842

Compensazione

Dr. Paul F. McKenzie, Ph.D. (Chemical Engineering), has been Chief Operating Officer at CSL Behring LLC since 2019. Dr. McKenzie serves as Chief Operating Officer at CSL Plasma Inc. Dr. McKenzie had been C...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul McKenzie	MD, CEO & Executive Director	1.7yrs	US$8.18m	0.0047% € 4.0m
Joy Linton	Interim Executive Vice President of CSL Behring	less than a year	US$3.73m	0.0025% € 2.1m
Andy Schmeltz	Executive Vice President of CSL Behring Business Unit (Leave of Absence)	1.3yrs	US$4.07m	0.00044% € 367.9k
John A. Levy	Interim Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Chris Cooper	Head of Investor Relations	no data	Nessun dato	Nessun dato
Gregory Boss	Executive VP of Legal & General Counsel	15.8yrs	US$2.31m	Nessun dato
Roanne Parry	Chief Human Resources Officer	less than a year	Nessun dato	Nessun dato
Andrew Nash	Senior Vice President of Research	no data	Nessun dato	Nessun dato
William Mezzanotte	Executive VP & Head of Research and Development	6.1yrs	US$2.14m	Nessun dato
Mark Hill	Chief Digital Information Officer & Executive VP	4.1yrs	Nessun dato	Nessun dato
Deirdre BeVard	Senior Vice President of Research & Development Strategic Operations	no data	Nessun dato	Nessun dato
Herve Gisserot	Senior VP & GM of Vifor	1.7yrs	Nessun dato	Nessun dato

1.7yrs

Durata media

59yo

Età media

Gestione esperta: Il team dirigenziale di CSJA non è considerato esperto (durata media 1.7 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul McKenzie	MD, CEO & Executive Director	1.9yrs	US$8.18m	0.0047% € 4.0m
Megan Clark	Independent Non Executive Director	8.8yrs	US$242.44k	0.0011% € 911.3k
Alison Watkins	Independent Non-Executive Director	3.3yrs	US$240.56k	0.00077% € 643.8k
Carolyn Hewson	Independent Non-Executive Director	4.9yrs	US$237.09k	0.00047% € 393.0k
Brian McNamee	Independent Non-Executive Chairman	6.8yrs	US$604.85k	0.026% € 21.9m
Robert Cuthbertson	Non-Independent Non-Executive Director	6.1yrs	US$221.35k	0.015% € 12.2m
Marie McDonald	Independent Non-Executive Director	11.3yrs	US$215.19k	0.00088% € 735.7k
Samantha Lewis	Independent Non-executive Director	less than a year	US$91.12k	0.00041% € 342.8k
Elaine Sorg	Independent Non-Executive Director	less than a year	Nessun dato	Nessun dato

4.9yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CSJA sono considerati esperti (durata media dell'incarico 4.9 anni).

CSL Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces Resignation of Pascal Soriot from the Position of Non-Executive Director, Effective 1 February 2021

Recent updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

Vifor Says Regularly in Talks with Other Market Participants After Reports

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

CSL Limited Provides Financial Guidance for Fiscal 2022

Seqirus Announces Health Canada Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older

CSL Limited to Report First Half, 2021 Results on Feb 18, 2021

CSL Limited Announces Resignation of Pascal Soriot from the Position of Non-Executive Director, Effective 1 February 2021

CSL Limited Announces Management Changes

CSL Limited (ASX:CSL) completed the acquisition of Vitaeris Inc.

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media